OTLK
Outlook Therapeutics, Inc.
Set alert
0.47 USD -0.03 -5.15%
0.45 Day range 0.4929
0.198 52-week range 2.47
- YTD
- -70.37%
- 1 year
- -62.25%
- Open
- 0.49
- Prev close
- 0.4935
- Mkt cap
- 113.96M
- Vol
- 4.79M
- Avg vol
- 10.25M
- EPS
- -0.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.45
- High
- 0.4929
- Forward P/E
- -0.55
- Beta
- 0.63
- Short ratio
- 1.26
- Inst. own
- 35.63%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 27, 2024
- 50-d avg
- 4.24
- 200-d avg
- 6.73
- 1y target
- 24.80
Key statistics
- Market cap
- 33.59M
- Enterprise value
- 34.76M
- Trailing P/E
- 0.00
- Forward P/E
- -0.55
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -5.89
- Beta
- 0.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -43.59M
- Total cash
- 32.02M
- Total debt
- 32.72M
- Return on equity
- 0.00%
- Shares outstanding
- 23.66M
- Short % of float
- 25.71%
- 50-day average
- 4.24
- 200-day average
- 6.73
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 24.80 +5198.0% upside
Now 0.4681
- Target (low)
- 9.00
- Target (mean)
- 24.80
- Target (high)
- 38.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy1
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Dec 27, 2024
Expected Dec 27, 2024. Consensus EPS estimate -0.90.
Financials — quick view
OTLK Revenue — quarterly 8.70K
OTLK Net income — quarterly -20.32M
OTLK EPS — quarterly -0.15
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 27, 2024 | Sep 1, 2024 | -0.83 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -1.06 | -0.83 | +0.23 | +21.70% |
| May 15, 2024 | Mar 1, 2024 | -0.88 | -1.55 | -0.67 | -76.14% |
| Feb 14, 2024 | Dec 1, 2023 | -1.00 | -0.80 | +0.20 | +20.00% |
| Dec 22, 2023 | Sep 1, 2023 | -1.00 | -1.00 | 0.00 | 0.00% |
| Aug 14, 2023 | Jun 1, 2023 | -0.80 | -1.60 | -0.80 | -100.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Chardan Capital | down | Buy | Neutral |
| Nov 29, 2024 | BTIG | main | Buy | Buy |
| Nov 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | Chardan Capital | main | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- outlooktherapeutics.com
News
- Xenetic Biosciences (NASDAQ:XBIO) versus Oncobiologics (NASDAQ:OTLK) Critical Analysis
- Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
- Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion
- Outlook Therapeutics Files Application With Centers For Medicare & Medicaid Services Seeking Healthcare Common Procedure Coding System Level II J-Code For LYTENAVA To Treat Macular Degeneration
- Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
- Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
- Reviewing Synlogic (NASDAQ:SYBX) and Oncobiologics (NASDAQ:OTLK)
- Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
- Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5
- Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Your note
Sign in to keep a note on OTLK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAGNON TERRY | Chief Operating Officer | Sale | Apr 19, 2023 | 653,058 |
| EVANSON JEFF | Officer | Purchase | Mar 6, 2024 | 808,459 |
| HADDADIN YEZAN MUNTHER | Director | Purchase | Mar 27, 2024 | 5,048 |
| KENYON LAWRENCE A. | Chief Financial Officer | Purchase | Sep 25, 2024 | 5,946 |
| SUKHTIAN GHIATH M | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Mar 17, 2024 | 0 |
| SYNTONE VENTURES, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 14, 2024 | 1,705,440 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tang Capital Management, LLC | 6.59% | 1,559,560 | 2.21M | Sep 29, 2024 |
| Great Point Partners LLC | 5.47% | 1,293,028 | 1.84M | Sep 29, 2024 |
| Blackrock Inc. | 4.42% | 1,044,988 | 1.48M | Sep 29, 2024 |
| Vanguard Group Inc | 3.62% | 855,876 | 1.22M | Sep 29, 2024 |
| Altium Capital Management, LP | 2.29% | 541,549 | 769.00K | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 1.90% | 450,000 | 639.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.87% | 442,511 | 628.37K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.56% | 369,414 | 524.57K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.19% | 281,280 | 399.42K | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.44% | 103,672 | 147.21K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 82,266 | 116.82K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.34% | 79,464 | 112.84K | Aug 30, 2024 |